Nubratori, Inc.
FDA 503B outsourcing facility
Torrance, California
Key Takeaways
- FDA-registered 503B outsourcing facility since 2017
- Sterile compounding from bulk substances: Yes
- Last FDA inspection: December 11, 2025
- 1 FDA drug recall on record (2025)
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- February 24, 2017
- Most recent registration
- December 3, 2025
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- December 11, 2025
The FDA last inspected Nubratori, Inc. on December 11, 2025. Investigators issued a Form FDA 483 listing inspectional observations at that visit. The FDA has not yet determined whether further action will be taken.
FDA recall history
Nubratori, Inc. has 1 FDA drug recall on record in 2025, based on the FDA enforcement database. Breakdown: 1 Class II.
Recall reasons on record include labeling: incorrect or missing lot and/or expiration date: individual vials of dexonto.
| Date | Class | Product | Reason |
|---|---|---|---|
| April 2025 | Class II | Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL), Rx Only, 12 - 5 mL Single Dose Units per box, Preservative Free | Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are la |
FDA recall classes signal severity, not intent: Class I means a reasonable probability of serious harm, Class II a temporary or reversible risk, Class III a violation unlikely to cause harm. Sterile compounders routinely recall lots as a precaution. FDA definitions.
What this facility compounds
Nubratori, Inc. reports compounding 12 distinct active ingredients to the FDA Outsourcing Facility Product Report (most recent reporting periods).
- Baclofen
- Bupivacaine Hydrochloride; Lidocaine Hydrochloride
- Dexamethasone Sodium Phosphate
- Dexamethasone Sodium Phosphate; Lidocaine Hydrochloride
- Diclofenac Sodium
- Epinephrine
- Gabapentin
- Ketamine Hydrochloride
- Ketoprofen
- Lidocaine
- Lidocaine Hydrochloride; Tetracaine Hydrochloride
- Naltrexone Hydrochloride
Location
381 Van Ness Ave Ste 1507, Torrance, CA 90501-7220
Satellite and street imagery via Esri. Open larger map.
Contact
FDA-registered contact: Gulshakar Khwaja, 310-218-4153. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Nubratori, Inc. with the California State Board of Pharmacy.
503B facilities in California
California has 7 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in California.
Frequently asked questions
Is Nubratori, Inc. registered with the FDA?
Yes. Nubratori, Inc. is a registered 503B outsourcing facility, first registered with the FDA on February 24, 2017 and most recently registered on December 3, 2025.
Has Nubratori, Inc. been inspected by the FDA?
The FDA last inspected Nubratori, Inc. on December 11, 2025. A Form FDA 483 was issued.
Has Nubratori, Inc. had any FDA drug recalls?
Nubratori, Inc. has 1 FDA drug recall on record (2025) in the FDA enforcement database.
What does Nubratori, Inc. compound?
Nubratori, Inc. reports compounding 12 active ingredients to the FDA.
Where is Nubratori, Inc. located?
Nubratori, Inc. is located in Torrance, California (381 Van Ness Ave Ste 1507).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026. Recall history from the FDA openFDA drug enforcement database, retrieved June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Nubratori, Inc.. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.